ClinicalTrials.gg
Not yet recruitingNCT07595198Updated May 19, 2026

Platelet-Rich Fibrin (PRF) vs Bone Graft With Membrane for Ridge Preservation After Tooth Extraction

An interventional study of Platelet-rich fibrin (PRF) and Freeze-dried bone allograft in Extraction, Tooth, Tooth Fracture and Tooth Crown Fracture, sponsored by Ohio State University. Not yet recruiting. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Ohio State University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study uses a natural material called Platelet-Rich Fibrin (PRF) to help improve healing after tooth removal. PRF is made from your own blood. A small amount of blood is taken from your arm and spun in a machine to make a thick, sticky layer full of platelets. These platelets help your body heal. PRF acts like a "natural bandage" and may help your gums and bone heal faster. Because it comes from your own body, it is safe and lowers the chance of infection or problems.

The goal of this research is to see if adding PRF to a bone graft (used to fill the tooth socket after extraction) can help the area heal faster and grow more new bone.

If you join this study, it will last about 4 months. You will have two teeth removed, and each socket will get a different treatment:

  1. One socket (test side) will get PRF + bone graft (this combination is also called "sticky bone").
  2. The other socket (control side) will get a bone graft + a covering called a barrier membrane (made of collagen).

We will compare how well the two sides heal by looking at:

  1. How the gums close over the area
  2. How much pain you feel
  3. How much the bone changes
  4. How much new bone grows You will come to the clinic for about 9 visits in total. These visits are part of your regular treatment, along with a few extra steps for the study.

One possible risk is bruising or soreness from the blood draw. If we cannot collect enough blood (about 60-80 ml) because your veins are too small or hard to find, you will not continue in the study, and both sockets will be treated using the control method (bone graft + membrane).

02

Conditions studied

  • Extraction, Tooth
  • Tooth Fracture
  • Tooth Crown Fracture
  • Root; Fracture

Keywords

  • Platelet Rich Fibrin
  • Extraction, tooth
03

In context

Tooth Fractures

37 studies on the registry are indexed under Tooth Fractures; 9 are open to participants now.

This study's planned enrollment of 14 is below the median of 40 across 33 interventional studies indexed under Tooth Fractures.

Browse Tooth Fractures studies →

Lead sponsor

Ohio State University is the lead sponsor of 663 studies on the registry; 148 are open to participants now.

Of its 67 completed or terminated interventional studies of FDA-regulated products, 49 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients of age between 18-80.
  2. Non-smokers or former smokers with at least a 5-year successful cessation history.
  3. Patients with normal systemic health (ASA-I) or well-controlled/stable systemic conditions (ASA-II), such as diabetes with \< 7.0%, no recent acute myocardial infarction and cerebrovascular accidents within 6 months, or any for periodontal or implant surgery.
  4. Patients treatment planned for extraction and ridge preservation for at least 2 non-adjacent single-rooted teeth.

Exclusion criteria

Exclusion Criteria:

  1. Current smokers, smokers who have quit \<5 years prior to study entry.
  2. Pregnant or lactating women
  3. Patients with substance or alcohol abuse
  4. Patients with a history of antiresorptive therapy, head and neck radiotherapy, and chemotherapy for malignant tumors
  5. Other systemic conditions or medications affecting wound healing.
  6. Poor plaque control with plaque score > 20%
  7. Active/untreated odontogenic and periodontal infections
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    PRF-solidified bone graft

    Extraction socket is grafted with freeze-dried bone allograft (FDBA) mixed with autologous platelet-rich fibrin (PRF) to form a cohesive graft, without placement of a barrier membrane.

    Biological: Platelet-rich fibrin (PRF) · Device: Freeze-dried bone allograft

  • Active comparator
    Bone Graft With Collagen Membrane

    Extraction socket is grafted with freeze-dried bone allograft (FDBA) and covered with a resorbable collagen membrane for ridge preservation.

    Device: Freeze-dried bone allograft · Device: Collagen barrier membrane

Interventions

  • Autologous platelet concentrate prepared from the participant's blood and applied to the extraction socket, mixed with bone graft.

  • DeviceFreeze-dried bone allograft

    Human-derived bone graft material used to fill extraction sockets for ridge preservation

  • DeviceCollagen barrier membrane

    Resorbable membrane placed over the grafted socket to stabilize the graft and prevent soft tissue ingrowth.

06

What researchers measure

Primary outcomes

  1. Change in alveolar ridge dimensions

    Change in alveolar ridge width and height will be measured by superimposing baseline and 4-month follow-up cone-beam computed tomography (CBCT) images at standardized cross-sectional locations corresponding to the extraction sites.

    Time frame: 4 months after ridge preservation (prior to implant placement)

Secondary outcomes

  1. Wound healing (re-epithelialization)

    Soft tissue wound closure over extraction sites will be assessed using serial intraoral scans and analyzed to quantify changes in wound area over time.

    Time frame: 1, 2, 3, and 4 weeks after ridge preservation

  2. Percentage of new bone formation

    Bone core biopsies obtained at implant placement will be analyzed histologically to determine the percentage of newly formed bone within the grafted sites.

    Time frame: 4 months after ridge preservation (at implant placement)

  3. Crestal soft tissue thickness

    Soft tissue thickness at the alveolar crest will be measured clinically using a periodontal probe at the time of implant placement.

    Time frame: 4 months after ridge preservation (at implant placement)

  4. Postoperative pain score

    Participant-reported pain will be assessed using a visual analog scale (VAS, 0-100), where higher scores indicate greater pain intensity.

    Time frame: 1, 2, 3, and 4 weeks after ridge preservation

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
May 19, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2027
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07595198
Responsible party
Sponsor
First posted
May 19, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
May 19, 2026

Study contacts

Siraj Zabadi, DDS
Contact
Zabadi.1@osu.edu
614-206-0298
Guo-Liang Cheng, DDS, MS
Contact
cheng.712@osu.edu

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: P-prf

Start the discussion